Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just my thoughts and opinion, unless you plan on holding for a very long time, it might be a bit greedy to go for .0006. Flippers/traders won't allow it to go that high. And there is no forseeable news to create the type of volume to get it there. Good luck to you though. .0006 would be a nice paycheck.
I'm in for million. Will add more later. Easiest decision I ever made.
Read the 10Q.
Article: "Is Drug Development Starting To Pick Up Again?"
Recently, Tony Marino on News Hawk Review, discussed NewCardio's QTinno solution and how it may contribute to a rebound in drug development activity.
http://newshawksreview.com/is-drug-development-starting-to-pick-up-again/42043/
All done for 2010. They will hopefully have some stuff to release by mid January, according to the company. In the meantime, with any luck, we'll see millions of more shares sold between now and then.
NWCI on Inside Business/FOX
Pardon me for preaching, but these .0000 level boards are pretty much all the same. Posts that are pro, posts that are con. The pros quote potential, product, and 'to da moon' future movements to a .01 and more. The cons talk about dilution, R/S, shady ceo's and 'No-Bid here we come's'. Literally every board of .0000's are pretty much cut and paste.
As far as this stock is concerned, it is following typical .0001 behavior. It is making the 'get rich quick' investors loose money and the '1-2 tick' traders make money. History of multiple .0000's behavior, showed that the CEO interview last week would cause a massive selloff. Couldn't of been more predictable.
For the majority of traders, including myself, these stocks and this one in particular, are great for making money for gas, groceries, monthly bills and Sunday football tabs at the bar. They will very rarely buy you the boat or the BMW, unless you're really f'n good at it. Which means hours of research day in and day out and having the skill to trade without emotion.
This one will not go to a penny and it will not go to a 'no-bid'. It will continue to float around .0002-.0006 regardless of what the company says or does.
As for my positive contribution to this board and where I think it is headed, I think it'll go up a few ticks, perhaps .0005, if it gets upgraded again on the pinkies. I will then sell and buy a nice bottle of scotch to drink with my family. Then buy the stock again when it repeats the cycle.
5th Annual Cardiovascular Risk Assessment Summit
Examine Regulatory Guidelines and Innovative Approaches to Assess Cardiovascular Risk
January 26 - 27, 2011
Alexandria , VA
Newcardio Inc, although they will not be presenting, they will be there to network.
Some of those that will be in attendance are:
Merat Bagha, President, CEO, Tiba Medical, Inc.
Richard C. Becker, M.D., Professor of Medicine, Divisions of Cardiology and Hematology, Duke University School of Medicine, Duke Clinical Research Institute
Charles I. Berul, M.D., Chief, Division of Cardiology, Children’s National Medical Center; Professor of Pediatrics, George Washington University
Borje Darpo, M.D., Ph.D., Global Medical Director, iCardiac Technologies
Robert P. Fiorentino, M.D., MPH, Medical Officer, Cardiovascular and Renal Products, Food and Drug Administration
Kathleen L. Gabrielson, DVM, Ph.D., Associate Professor, Johns Hopkins University School of Medicine
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Chairman; QT Working Group, Abbott
David E. Gutstein, M.D., Chair of the Cardiovascular Organ Specific Safety Board, Merck
Jeffrey Heilbraun, MS, Senior Manager, Scientific Affairs, CoreLab Partners Inc.
Luana Pesco Koplowitz, M.D., Ph.D., FCP, FFPM, President, Chief Medical and Scientific Officer, DUCK FLATS Pharma, LLC
Thomas Langenickel, M.D., Ph.D., Medical Director, Discovery Medicine/Cardiovascular and Metabolic Diseases, Co-Chair, CV Advisory Group, Bristol-Myers Squibb
Danshi Li, M.D., Ph.D., Associate Medical Director, Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb
Catherine MacLeod, M.D., Director of Clinical Research, Department of Clinical Pharmacology, Merck Research Laboratories
Marek Malik, M.D., Ph.D., DSc, FACC, FESC, FHRS, Professor of Cardiac Electrophysiology, St. Paul’s Cardiac Electrophysiology, London
Royce Morrison, M.D., CPI, Director of Clinical Strategy, Charles River Laboratories
Adel Nada, M.D., MS, Director, Clinical Pharmacology Medical Department and Cardiac Safety Clinical Systems, Abbott
Robert Pordy, M.D., FACP, Head, Cardiovascular and Metabolism Therapeutics, Regeneron
Anthony Robinson, MSN, CRNP, Associate Director, Clinical Pharmacology, Shire
Ignacio Rodriguez, M.D., Director, Safety Risk Management, Roche
Jeremy N. Ruskin, M.D., Director, Cardiac Arrhythmia Service, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School
Philip T. Sager, M.D., FACC, FAHA, FHRS, Pharmaceutical Consultant, Chair of the Scientific Oversight Committee, Cardiac Safety Research Consortium
Lawrence Z. Satin, M.D., F.A.C.C., Chief Medical Officer, Cardiocore
Polina Voloshko, M.D., Vice President of Medical Operations, Cardiocore
Robert Wallis, Ph.D., Executive Director, Head of Centres of Emphasis, Drug Safety Research and Development, Pfizer
Yes, indeed there is. And if you are invested, it's important not to get freaked out by the large pps shifts. The MM's use large spreads to create high volatility. Its best to not look at it day to day.
There's no way in hell that people here will allow this stock to sit on .0006. It's hard enough to keep the .0002's. I'd rather have as many people as possible, continue to sell off at these low levels, on no news, then at higher levels with news.
Got my feet wet with a 100K shares today. Will add much more if this level stabilizes and daily volume goes past 60mill.
Excerpt from Benchmark report for Qtinno. Hope this helps.
We estimate that NewCardio can earn 80%-90% gross margin on QTinno studies because this
revenue is primarily a software license. Management estimates that NewCardio has the capacity to
support 8-9 QTinno studies per quarter without adding additional staff. Management estimates
that the Company could be break-even at approximately 3-5 studies per month. We estimate that
to break even at a $350,000 monthly cash burn, NewCardio needs to generate approximately $0.4
million in monthly revenue at 85% gross margin. We estimate that NewCardio would break even if it
performed one Thorough and three ascending doses studies per quarter. Studies range in size but
our forecasts are based on revenue of approximately $200,000 per Thorough QT study and
$54,000 per ascending dose QT study, plus some related services and other revenue.
We estimate the total addressable market for ECG analysis in cardiac safety pharmaceutical trials is
approximately $750 million based on data from Health Research International and the current
industry leader, eResearch Technologies. Of this, we estimate the market available to
NewCardio for Thorough QT studies is approximately $12 million - $20 million at 60-100 Thorough
QT studies per year at an average of approximately $200,000 per study. We estimate the market
for ascending dose studies is $8.1 million - $13.5 million based on 150-250 studies per year at
approximately $54,000 per study. The majority of the market is comprised of ECG monitoring of
patients in phase-II, phase-III and phase-IV studies. This is not QTinno’s initial focus but offers
significant long-term expansion opportunity.
We estimate that CardioBip’s global market
opportunity in episodic diagnosis and cardiac monitoring is approximately $2.6 billion annually. We
estimate that Cardio3KG’s market opportunity in acute diagnosis is approximately $1.4 billion
annually.
I got it from IR, not Joe. I think that when people are able to put their emotions and frustrations aside and look at this from outside the box, logic will win the day. Joe isn't some boogeyman in the closet trying to steal all of our money. They will kick off the new year with some positive developments.
I almost sold at 5 as well, but chose not to. In hindsight, yeah I wish i did. You just never know with these penny's. I chose to sell early on ZVTK, only to watch it go up another 64 ticks. Lol, damned if you do, damned if you don't. Its been one of those years for me. Can't wait to start fresh in 2011.
Well,IR said, in regards to the restructure, "details are still being worked on but it is unlikely a definitive agreement will be in place subject to shareholder approval until sometime in January."
That means that they will need shareholder sentiment to be positive. Which means that they will definitely have to throw out some bones.
Looks like those .0006's are selling! Nice 10 mill block went. the .001's are starting to loose ground. .0009 bids increasing.
There will be plenty of sellers over the next 2 weeks merely for tax purposes. Put this puppy to bed. It's done for the year.
EPGL is essentially finished for the year. All business now is related to closing out 2010. Better to finish the year with a solid foundation and start off 2011 building on it. In January, we can expect the restructure agreement, the Army contract, the Nutra Guide, Foreign Language deal, etc.
The only reason it's at .0001 is because everybody here put it there. Not Joe. Had he any motivation to pump and dump, it would of went a lot higher then .0006. It would horrible for them to release any news right now. It would be completely wasted as everybody would sell immediately for tax purposes, etc. I like Joe' strategy. And I'm sitting on a 75% loss right now. I would prefer that people keep selling until EOY.
Link to Admiral Mullen's speech.
It won't play on a Mac. So I can't view it. I'd like to know its any good though.
https://eparent.webex.com/cmp0306l/webcomponents/docshow/docshow.do?javaEnable=true&siteurl=eparent&rnd=0.138749078553829
It means they gave away another 91 million shares for .0006. This is getting comical. Whoever got the shares, if they like the company and decide to hold, then we'll stay at.001. If they decide to cash out then we are venturing on the yellow brick road to .0001
NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study
QTinno reduces measurement variability and improves data quality in independent validation study
SANTA CLARA, CA (December 10, 2010) -
PR Newswire - NewCardio, Inc., (OTC BB: NWCI) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of QTinno™ on its "testing" ECG dataset. The CSRC blinded "testing" dataset, comprised of 11,672 electrocardiograms (ECGs) from the moxifloxacin and placebo arms of a recent parallel-group Thorough QT Study. The CSRC blinded study results show, by a variety of analytical approaches, that QTinno accurately detects moxifloxacin-induced QT interval prolongation with statistically significant and substantial reductions in measurement variability compared to sponsor-submitted data. In QT studies, lower measurement variability increases the quality of study results and may enable future studies to be done in a more cost effective manner, thereby potentially reducing expenses for cardiac safety studies, which is a significant value proposition for QTinno users.
The study results were presented yesterday (December 9, 2010) to key representatives from the Food and Drug Administration (FDA), pharmaceutical companies, and academia by Samuel George, MD, FACC, JD, NewCardio's Senior Medical Advisor, at the CSRC's Annual Meeting. The CSRC makes its blinded "testing" dataset available to any cardiac safety technology developer who accepts the conditions that the blinded analysis is conducted independently by the CSRC without any company involvement, and that any results obtained will be made public by the CSRC (www.cardiac-safety.org/ecg-database/rules_of_engagement.pdf). NewCardio is the first such entity to accept the CSRC conditions and complete the study.
Vincent Renz Jr., NewCardio's President and CEO commented, "We are very excited that QTinno was the initial automated cardiac safety solution whose performance was evaluated against the CSRC blinded 'testing' data set, for two reasons. First, based on the QTinno validation studies done to date with partners from Pharma, clinical trial service providers and academia, we expected, and realized, statistically significant results from this blinded drug safety study. QTinno has consistently returned highly accurate results with lower variability than other comparator methods, be it manual, semi-automated or automated, just as it did in the CSRC study. And second, it provided another opportunity for us to enhance our collaborative efforts with the CSRC in utilizing the underlying science and technology of QTinno to advance the current state of cardiac safety testing."
In the study, the CSRC made detailed comparisons of QTinno measurements to those originally submitted to the FDA by a drug sponsor in an FDA mandated cardiac safety drug study as required under the ICH E14 Guidance. The primary endpoint of this analysis was the accurate detection of the control drug's (moxifloxacin) effect on QT intervals, and the precision of the submitted measurements. Detailed results of this study will be submitted for publication in a peer-reviewed journal in the near future, and will be posted on the NewCardio website after peer-reviewed publication.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, stated, "We commend the CSRC for the excellent design and execution of this very important study, and we are proud that QTinno once again proved its accuracy in this rigorous examination. The study results provide compelling, and completely independent evidence that QTinno returns industry leading, fully automated accuracy in clinical drug studies, and does so with significantly reduced measurement variability. We believe that QTinno has the potential to increase the power of future studies and reduce study expenses for pharmaceutical drug sponsors."
Mr. Renz, continued, "Validation of new technologies is critical, and FDA representatives have consistently stated that they are willing to accept clinical results using automated ECG measurements from any validated methodology and the results from all of our validation efforts, which now include this CSRC study, more than meet FDA standards for validation, and as such QTinno is acceptable to the FDA. We believe that there will come a point where, based on the quality of performance, the industry will move from validation to the acceptance of methodologies which not only deliver high quality results, but do so in a more timely and cost effective manner. The blinded CSRC study results reinforce the strength of QTinno's performance with both current and potential customers and, more importantly we believe this clearly establishes the critical role of QTinno as the drug development industry accelerates their adoption of the higher quality, cost effective cardiac safety analysis."
About QTinno Technology
NewCardio's patented QTinno 3-D ECG software technology is a novel, fully automated program for evaluating QT and other timing intervals relevant for assessing drug cardiac toxicity in drug development. It provides fast, accurate and precise QT data from a broad range of challenging ECGs and enables reliable, automated identification of key cardiac events. Pharmaceutical sponsors and clinical research organizations, which are mandated by the FDA to test new drugs for potential cardiac toxicity, are expected to benefit from QTinno's faster, more accurate and less expensive assessment of cardiac status.
The badder, the better. Cheaper it gets the cheaper 2million shares will be. .0001 would be a dream!
I don't think so. When the 29th happened, so many bought above .002.
Then it sold off too quickly for them to gather their senses. Additionally, I'm sure all of them figured it would bounce backup. Smart ones then sold at .0018. Inexperienced ones held on. I'm betting those who bought between .001 and .002 sold first and then those whole were recipients of the .0008's unloaded. Now, the .0006's are unloading.
.062. Sure beats .198
I am loving this tax write off, sell off! I've been able to average down to a very sexy pps compared to where I was. If the gifts keep on coming, I'll keep on buying.
True, the only people selling are those that can still make a meager profit. The hundreds of millions of shares that were bought on the 29th, above .002 are still holding
Don't know if I would label it as 'strong hands'. Perhaps, 'slightly more patient hands'.
Regarding the debt restructuring plan, I'm thinking of the current sellers as "no" votes, where as those holding and newbies are "maybe" votes. With news down the road, there will be some "yes" votes. Getting full control of the company is huge for them. They won't risk loosing the vote with the current bagholders. Bust out your snicker's bar. We're gonna be here a while.
Nope, If I wasn't already involved in it, I wouldn't buy it because there isn't any indication of upward movement within a few days. Nor would I recommend it. Nobody is invested in this company for it's product, management or long term future potential. There are no investors in this stock. Only traders/flippers. Management could give a f$^% about anyone here. Why the hell should they? Nobody here gives a f%*& about them.
Joe greatly misjudged trader's sentiment, thinking that releasing non-concrete/fluffy info would create 'investors' for the company. Having failed, he is re-grouping. That will take a while.
I will hold though. I do believe the more people that sell, Joe will be more inclined to continue with the debt restructuring process. To release it now would be like putting it in front of the firing squad.
I find it highly amusing that people are pleading with Joe for PR's. "Hey Joe, please release something to increase the PPS so I can pull my money out of your company!" If only people didn't make fun of his floral wall patterns, we might of had a chance. ;).
In my humble opinion, Joe will wait until most of you grow impatient, sell and are gone. He knows that he isn't going to get his yes vote with who's invested now. He needs new blood. It's now a question of who can wait longer. I'm loving the fact that people are bailing right now. The more that bail, the sooner this thing will get moving again. So please, please sell!
MM's are stacked heavy on the .0011 bid. Yesterday we had 11 of them sitting on it. Today we have 7 with another 3 on .0012. It would take a massive selloff to break that support wall. With a large majority of current bagholders above .002 that are committed to hold, there won't be enough selling pressure to break it.
There's actually 1.75 billion AS with 700mil OS.
That gives them 1.05Billion left. at .0006,just over 600K
Still bad though.
Timing will be a catalyst for sure and what helix has going on at the time of the approval, if there is an approval that is. If there is money to be made, Bluewater will work with them.
I doubt Bluewater would sell off the patent. I'm willing to bet that if the patent is passed that Helix will pay them off the 600+K either from outside investors that are waiting on the patent or by diluting more shares. They still have 1.05 billion left to dilute. Plus, nobody can say what Bluewater will do. They know more about Helix's situation than any of us do.
See what happens when people make fun of a man's floral patterns.
NWCI Newcardio inc. Test results from the CSRC test to be presented at FDA headquarters on thursday
http://www.otcmarkets.com/stock/NWCI/news
I plan on buying more in the millions once it falls below .001
I only went for 100K at .0013. Just in case something happens that keeps it over. I suspect something is up.
Too tempting not to buy at .0013. Had to do it. Kinda like betting on 'snake eyes' while playing Craps.
Yup. And Joe isn't going to do anything to appease swing traders. Time to set up camp and wait.
NWCI NewCardio's Chief Technical Officer, Dr. Dorin Panescu, Named 2011 IEEE Fellow
http://www.b2i.us/profiles/investor/ResLibraryView.asp?ResLibraryID=42160&GoTopage=1&Category=1202&BzID=1645
3 More Days! Get em while you still can.
Accumulation is sky high. Most volume today since last August. MM's running around like ants on potato salad. All leading up to December 9 test results.